Global Biomanufacturing Trend Analysis: Capacity Expansion, M&A Activity, And Regional Footprint Landscape

Report Summary

The global biomanufacturing sector is undergoing a strategic transformation driven by increased demand for biologics, evolving therapeutic modalities, and growing emphasis on regionalized manufacturing. This trend report provides an in-depth analysis of the biomanufacturing landscape, focusing on three core themes: M&A activities, global capacity expansion, and regional footprint dynamics. While capacity expansion is increasingly geared toward flexibility and speed, merger and acquisition activity underscores the competitive race for technological advancement and scale. This analysis serves as a strategic guide for CDMOs, biopharma innovators, and investors seeking to understand growth signals and regional shifts shaping the future of biologics manufacturing.

Global Biomanufacturing Trend Analysis: Capacity Expansion, M&A Activity, and Regional Footprint Landscape

Attributes	Details
Areas of Research	M&A activity trends, capacity expansion initiatives, regional manufacturing footprint, and CDMO & biopharma strategy evolution across biologics segments
Report Representation	Comprehensive market trend analysis in PDF format supported by real-world case examples, capacity data points, and regional benchmarking
Geographic Coverage	Global Coverage (North America, Europe, Asia-Pacific, Rest of the World)
Executive Summary	Overview of current biomanufacturing shifts post-COVID, key market consolidations, regional capacity trends, and forward outlook (2021-2033)
Key Trend Themes	Rising biologics demand and next-gen therapies Increased vertical integration and platform acquisitions Regional Reshoring
Capacity Expansion Highlights	Major greenfield projects (Samsung, WuXi, Resilience) Modular, single-use, and mRNA capacity investments
M&A Landscape	Strategic acquisitions by Lonza, Thermo Fisher, Fujifilm, etc. Deal rationale tied to ADCs, CGT platforms, and regional expansion
Regional Capacity Analysis	North America Europe Asia-Pacific RoW
Strategic Implications	Growing need for diversified geographic presence Increased investor interest in CDMOs with end-to-end capability
Technology Focus Areas	mRNA production, gene/cell therapy, single-use systems AI integration and smart manufacturing enablement

M&A Activities in the Biomanufacturing Sector

The biomanufacturing sector has witnessed significant consolidation and strategic acquisitions over the past few years. Between 2020 and 2024, M&A activity has been largely driven by the need for proprietary technologies, regional expansion, and capacity integration across biologics platforms. These transactions not only reflect the competitive push to build platform breadth but also highlight an increasing desire to provide end-to-end services for emerging therapeutic modalities.

CDMOs are particularly focused on acquiring key technology capabilities such as viral vector production, plasmid DNA, fill-finish operations, and modular biologics capacity, all of which are critical for scaling both traditional biologics and advanced therapies like gene and cell therapy.

A growing number of deals are centered on cell and gene therapy platforms, where internal manufacturing capabilities remain limited, and speed-to-market is critical.

Overall, M&A continues to serve as a strategic lever for both legacy players and new entrants to gain competitive advantage through scale, platform diversity, and innovation access.

Company	Year	Target	Deal Value	Strategic Gain
Novo Holdings	2024	Catalent (CDMO)	$16.5 B	Massive expansion into biologics manufacturing
Ampersand	2024	Avid Bioservices (CDMO)	$1.1 B	Access to cGMP biologics production infrastructure
PCI Pharma Services	2025	Ajinomoto Althea (CDMO)	Undisclosed	North America-first sterile fill-finish capacity
Zydus	2025	Biologics plants (CA, USA)	$75 M + $50 M	Strategic CDMO foothold in the U.S. biotech hub
AstraZeneca	2025	EsoBiotec	Up to $1 B	Expands oncology cell therapy and CDMO platforms

Biomanufacturing Expansion Mapping

Between 2024 and 2025, global biomanufacturing capacity continues to scale rapidly as companies respond to growing biologics demand, mRNA and cell/gene therapy adoption, and the need for resilient, regional supply chains. Investments are largely concentrated in greenfield infrastructure, modular production lines, and technology-forward facilities that can handle diversified therapeutic pipelines.

A clear industry pivot is observed toward single-use bioreactor systems, continuous manufacturing, and multi-modality readiness with capabilities spanning mammalian, microbial, mRNA, and cell therapy production. These expansions are not just about volume they’re strategically engineered for speed-to-market, regulatory flexibility, and global redundancy.

The table below outlines key biomanufacturing expansion initiatives announced or completed between 2024 and 2025, showcasing how leading CDMOs and biopharma players are reshaping the global manufacturing landscape. These projects span across Asia, North America, and Europe, reflecting both the globalization and regionalization of biomanufacturing capabilities.

Biomanufacturing Expansion Initiatives

Company / Project	Date	Location	Capacity / Facility Type	Strategic Significance
Samsung Biologics – Plant 5 (Bio Campus II)	Apr 2025	Songdo, Incheon, South Korea	+180 kL; total capacity ≈ 784 kL; considering Plant 6 (~964 kL total)	Largest single-site CDMO capacity; supports ADC platforms and flexible biologics production
WuXi Biologics – Chengdu Microbial Site	Jun 2025	Wenjiang, Chengdu, China	15,000 L fermenter; DS & DP; ≥10 M vials/year; dual-chamber lyophilization	First dual-chamber lyophilizer in China; enhances peptide, plasmid DNA, VLPs; supports multi-modality expansion
WuXi Biologics – Massachusetts (U.S.) Facility	Operational 2025	Worcester, Massachusetts, USA	+12 kL commercial DS capacity (total MFG11 24 kL)	Adds U.S.-based commercial-scale manufacturing; strengthens dual‐sourcing strategy
Fujifilm Diosynth – Holly Springs Phase 1	Late 2024–2025	Holly Springs, North Carolina, USA	Modular cell culture; part of $3.2 B global investment; supports Regeneron 10‑yr, $3 B CDMO deal	Modular, rapid deployment capacity for large-scale biologics; secures long-term partnerships
Fujifilm Diosynth – Thousand Oaks Expansion	Nov 2024	Thousand Oaks, California, USA	Added 2 cGMP cell therapy suites; EMA‑certified	Boosts autologous/allogeneic cell therapy capacity; regulatory-certified cell therapy hub in California
Fujifilm Diosynth – Billingham Microbial Plant	2024	Billingham, UK	2 × 4000 L fermenters; tripled microbial throughput; ~£100 M	Scales up microbial biologics production in the UK; supports global biologics pipeline

Biomanufacturing Capacity Analysis by Key Regions

Between 2024 and 2025, the global biomanufacturing footprint has diversified rapidly as companies and governments actively reduce dependence on single-source supply chains and fortify local production ecosystems. Each region is adopting unique strategies driven by incentives, innovation strength, cost structure, government policy, and emerging public health needs.

North America maintains its leadership in innovation-driven biomanufacturing. It is propelled by federal initiatives, robust clinical-trial frameworks, and strategic investment in advanced CDMO facilities-particularly in fill-finish, gene/cell therapy, and mRNA production.
Europe continues to consolidate capacity in Germany, Ireland, Switzerland, and the UK, with expansions supported by regulatory coherence and a skilled labor force, especially in microbial and injectable biologics production.
Asia-Pacific-led by China, South Korea, and India-is experiencing accelerated growth. Lower production costs, supportive industrial policy, and rising CDMO investments make it a formal manufacturing powerhouse, supplying both domestic and global biologics pipelines.
Latin America & Middle East/Africa (MEA) are developing as vaccine, fill-finish, and packaging hubs. Efforts are centered on pandemic preparedness, regional access to biologics, and compliance with international standards driven by strategic partnerships and infrastructure funding.

The table below highlights major regional biomanufacturing expansions from 2024–2025, showcasing the diversification, scale, and strategic intent behind these investments.

Region	Key Projects & Companies	Highlights
North America	Fujifilm Diosynth is building a $1.2 billion biologics plant in North Carolina (Holly Springs), focused on cell culture production. Resilience is expanding its fill-finish capacity in Ohio and North Carolina. Jubilant HollisterStier is adding a new sterile manufacturing line in Washington state.	U.S. remains the innovation hub, with investments in gene therapy, sterile injectables, and biologics production.
Europe	Vetter Pharma is building a new injectable drug manufacturing site in Saarlouis, Germany, and expanding its plant in Ravensburg. Thermo Fisher is investing over $300 million in Ireland and Germany to boost sterile drug and biologics capacity.	Europe is focusing on injectable biologics, backed by skilled labor and strong regulatory systems.
Asia-Pacific	Samsung Biologics is expanding with Plant 5 in South Korea, aiming to become the world’s largest biologics manufacturer. WuXi Biologics opened new plants in China, Ireland, and Germany. India's CDMOs like Syngene and Biocon are expanding to meet U.S. and EU demand.	Asia is becoming a global biologics production center due to cost advantages and strong government support.
Latin America & MEA	Brazil and Mexico are investing in vaccine fill-finish and packaging facilities, often with international support. The Pan American Health Organization (PAHO) is funding local vaccine manufacturing projects in Latin America.	These regions are emerging hubs for vaccine and essential drug manufacturing for local and regional supply.
Global Trends	North America still holds the largest market share in biologics manufacturing Asia-Pacific is the fastest-growing region, with strong growth in mRNA and cell/gene therapy manufacturing.	Global biomanufacturing is shifting from centralized to regionally distributed models for resilience and speed.

Report Details

Need a Tailored Report?

Customize this report to your needs - add regions, segments, or data points, with 20% free customization.

Customize This Report

Or view our licence options:

ISO 9001:2015 & 27001:2022 Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

Trusted market insights - try a free sample

See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.

Customize This Report Download Free Sample